Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Davis
- Full Time Employees
- 73,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday
The Dividend ETF Quietly Outperforming the S&P 500
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Why MSTY Shareholders Are Facing Uncapped Losses Despite Weekly Distributions
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Tells Investors
Merck Stock, JPMorgan And Two Others Hit New Highs
Schwab vs. Vanguard: Which Dividend ETF Is Best for Your Portfolio?
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Stock Futures Quiet to End the Month, Quarter
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?